Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform
ReutersDec 17, 2025 1:08 PM
Dec 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:
ALNYLAM TO INVEST $250 MILLION TO ADD ENZYMATIC LIGATION PLATFORM TO U.S. MANUFACTURING FACILITY TO MEET GROWING GLOBAL DEMAND FOR RNAI THERAPEUTICS
ALNYLAM PHARMACEUTICALS INC - NEW CAPABILITIES OPERATIONAL BY LATE 2027
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Rocket Lab Stock Analysis: Why Is Rocket Lab Stock Price Soaring? Is Now a Good Time To Buy?
TradingKey - Even though Rocket Lab's stock price has seen substantial gains from its previous levels, we believe that Rocket Lab still offers speculative value.TradingKey
19 hours ago
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Cathie Wood Predicts Bitcoin Has Bottomed. Is Now The Best Time to Buy? How to Buy BTC?
Purchasing Bitcoin is generally divided into three stages: pre-transaction, during transaction, and post-transaction. Each stage requires careful attention, as losses can easily arise from operational errors, pitfalls, and other factors.TradingKey
Fri, Dec 19
Musk’s Next Ambition: Building a Space-Based AI Data Center
TradingKey - Musk has long resisted the idea of taking SpaceX public. After the Tesla take-private drama and the resulting SEC penalties (which cost him the chairmanship), he’s been wary of public market entanglements. But something’s changed—and fast.TradingKey
Thu, Dec 18
Tradingkey
